YUNNAN BAIYAO(SZ:000538)2023-06-13 08:26Company Overview - Yunnan Baiyao was established in 1902 and is recognized as a leading innovative representative of traditional Chinese medicine [2] - The company has been listed on the Shenzhen Stock Exchange since 1993 and has consistently provided dividends to shareholders for 30 years [2] - Yunnan Baiyao aims to integrate traditional Chinese medicine into modern life and continuously innovates its product offerings [2] R&D Investment - The company has increased its R&D investment, with over 1,200 R&D personnel and an investment of 343 million CNY in 2022, accounting for 2.68% of industrial sales revenue [3] - R&D expenses rose from 174 million CNY in 2019 to 337 million CNY in 2022 [3] Traditional Chinese Medicine Innovation - Yunnan Baiyao has 247 traditional Chinese medicine products and 354 related approvals, including 43 exclusive products and 53 exclusive approvals [4] - The company is actively involved in the secondary development of traditional medicine products and has initiated several key research projects, including treatments for COVID-19 and other health conditions [4] Market Value Management - The company places high importance on market value management by enhancing governance structures, improving information disclosure, and establishing a stable dividend mechanism to increase investor returns [6]